23. Comparison of results between 2004 Review and 2009 Update (Children < 24 months and/or HIV‐1 negative plus HIV‐1 positive children).
| Outcome | 2004 Results | Effect P‐value | I2 |
Hetero P‐value |
2009 Update |
Effect P‐value |
I2 |
Hetero P‐value |
Difference (%) |
| VE [95% CI] | VE [95% CI] | ||||||||
| Invasive pneumococcal disease (IPD) | |||||||||
| IPD, vaccine serotypes, ITT (Random) | 81 [65, 89] | P < 0.00001 | 2.4% | P =0.39 | 77 [58, 88] | P < 0.00001 | 36% | P = 0.15 | ‐4.94% |
| IPD, all serotypes, ITT (Random) | 67 [36, 84] | P =0.001 | 54.7% | P = 0.07 | 58 [34, 73] | P = 0.0002 |
48% | P = 0.07 |
‐13.43% |
| IPD, non‐vaccine serotypes, ITT (Random) | ‐12 [‐118, 43] | P = 0.75 | 0% | P = 0.96 | ‐6 [104, 45] | P = 0.86 | 0% | P = 0.95 | 50.00% |
| IPD, vaccine‐related serotypes, ITT (Random) | 38 [‐32, 71] | P = 0.22 | 0% | P = 0.56 | 40 [‐25, 71] | P = 0.17 | 0% | P = 0.73 | 5.26% |
| IPD, vaccine serotypes, ITT (Fixed) | 80 [66, 89] | P < 0.00001 | 2.4% | P = 0.39 | 77 [65, 85] | P < 0.00001 | 36% | P = 0.15 | ‐3.75% |
| IPD, all serotypes, ITT (Fixed) | 61 [44, 72] | P < 0.00001 | 54.7% | P =0.07 | 53 [39, 64] | P < 0.00001 | 48% | P = 0.07 | ‐13.11% |
| IPD, non‐vaccine serotypes, ITT (Fixed) | ‐12 [‐118, 43] | P = 0.75 | 0% | P = 0.96 | ‐6 [‐104, 45] | P = 0.86 | 0% | P = 0.95 | 50.00% |
| IPD, vaccine‐related serotypes, ITT (Fixed) | 38 [‐32, 71] | P = 0.22 | 0% | P = 0.56 | 40 [‐25, 71] | P = 0.17 | 0% | P = 0.73 | 5.26% |
| IPD, vaccine serotypes, PP (Random) | 78 [29, 93] | P = 0.01 | 50% | P = 0.11 | |||||
| IPD, all serotypes, PP (Random) | 69 [21, 88] | P = 0.01 | 70% | P = 0.02 | |||||
| IPD, non‐vaccine serotypes, PP (Random) | 32 [‐132, 80] | P = 0.54 | 0% | P = 0.87 | |||||
| IPD, vaccine‐related serotypes, PP (Random) | 40 [‐387, 93] | P = 0.63 | 0% | P = 0.64 | |||||
| IPD, vaccine serotypes, PP (Fixed) | 80 [60, 90] | P < 0.00001 | 50% | P = 0.11 | |||||
| IPD, all serotypes, PP (Fixed) | 59 [40, 73] | P < 0.00001 | 70% | P = 0.02 | |||||
| IPD, non‐vaccine serotypes, PP (Fixed) | 32 [‐132, 80] | P = 0.54 | 0% | P = 0.87 | |||||
| IPD, vaccine‐related serotypes, PP (Fixed) | 40 [‐387, 93] | P = 0.63 | 0% | P = 0.64 | |||||
| X‐ray defined pneumonia | |||||||||
| X‐ray defined pneumonia, ITT (Random) | 19 [10, 28] | P < 0.0001 | 0% | P = 0.53 | 25 [12, 36] | P = 0.0004 | 61% | P = 0.05 | 31.58% |
| X‐ray defined pneumonia, ITT (Fixed) | 19 [10, 28] | P < 0.0001 | 0% | P = 0.53 | 26 [19, 32] | P < 0.00001 | 61% | P = 0.05 | 36.84% |
| X‐ray defined pneumonia, PP (Random) | 35 [26, 42] | P < 0.00001 | 0% | P = 0.40 | |||||
| X‐ray defined pneumonia, PP (Fixed) | 35 [26, 42] | P < 0.00001 | 0% | P = 0.40 | |||||
| Clinical pneumonia | |||||||||
| Clinical pneumonia, ITT (Random) | 6 [3, 9] | P = 0.0006 | 18% | P = 0.30 | |||||
| Clinical pneumonia, ITT (Fixed) | 6 [3, 9] | P < 0.0001 | 18% | P = 0.30 | |||||
| Clinical pneumonia, PP (Random) | 6 [3, 10] | P = 0.001 | 11% | P = 0.34 | |||||
| Clinical pneumonia, PP (Fixed) | 6 [3, 10] | P = 0.0004 | 11% | P = 0.34 | |||||
| All‐cause admissions | |||||||||
| All‐cause admissions, ITT (Random) | 5 [‐10, 17] | P = 0.50 | 87% | P = 0.006 | |||||
| All‐cause admissions, ITT (Fixed) | 4 [‐1, 9] | P = 0.08 | 87% | P = 0.006 | |||||
| All‐cause admissions, PP (Random) | 6 [‐8, 19] | P = 0.38 | 85% | P = 0.010 | |||||
| All‐cause admissions, PP (Fixed) | 6 [0, 11] | P = 0.04 | 85% | P = 0.010 | |||||
| All‐cause mortality | |||||||||
| All‐cause mortality, ITT (Random) | 11 [‐1, 21] | P = 0.08 | 0% | P = 0.98 | |||||
| All‐cause mortality, ITT (Fixed) | 9 [‐1, 19] | P = 0.07 | 0% | P = 0.97 | |||||
| All‐cause mortality, PP (Random) | 14 [0, 26] | P = 0.05 | 0% | P = 0.95 | |||||
| All‐cause mortality, PP (Fixed) | 14 [0, 26] | P = 0.05 | 0% | P = 0.95 | |||||
Empty cells for particular outcomes in the 2004 review means that data were not available at that time or the results of only one study was available